Clinical Trial Study on Curcumin at MD Anderson

pdf file about fundraising study to use curcumin to treat NF tumors: http://texasnf.org/docs/MD_Anderson_Research.pdf

Well this is rather interesting. The actual cancer they are conducting clinical trials on using curcumin is Myeloma which my grandfather had as his second cancer.

So anyone out there with Myeloma (or Pancreatic) cancer, if you have run out of treatment options, there is currently a clinical trial being conducted at MD Anderson in Texas.

Here is the clinical trial study on the usage of curcumin for Myeloma. I will also include the link which you can access by clicking the lighthouse icon in my post title.

P.S. - clicking on the link above provides an easier to
read format of the study I pasted below. It will also bring you to the MD Anderson website for which you can view other clinical trials and treatment programs.


Study SummaryNo. 2003-0436:.......Myeloma......Saroj Vadhan-Raj......Palliative Care & Rehabilitation Medicine.
Study Summary Title
Study SummaryNumber:
2003-0436
Study Title:
Pilot Study of Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients with Multiple Myeloma.
Physician
New Patient Referral
Name:
Saroj Vadhan-Raj
Patients Call:
800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Dept:
Palliative Care & Rehabilitation Medicine
Referring MDCall:
800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Phone:
713-792-7966Contact us about clinical trials
.
General Information
Disease Group:
Myeloma
Supported By:
Sabinsa Corporation
Phase of Study:
N/A
ReturnVisit:
Every 4 weeks.
TreatmentAgents:
BioperineCurcumin
Home Care:
Curcumin and Bioperine are both in pill form, therefore, could be taken orally at home.
Treatment Loc:
Only at MDACC
EstimatedLength of Stayin Houston:
None for the treatment
Description/Intervention:
The goal of this clinical research study is to compare curcumin alone to curcumin given in combination with Bioperine in the treatment of multiple myeloma. The safety of these two treatments and how the disease responds will also be compared..
Study Objectives / Outcomes
(1) To evaluate clinical tolerance and response to curcumin alone and in combination with Bioperine in patients with multiple myeloma.(2) To compare the pharmacokinetics and pharmacodynamics of curcumin and curcumin + Bioperine and evaluate the effect of Bioperine on the bioavailability of curcumin.(3) To evaluate the biologic effects of curcumin alone and in combination with Bioperine on the expression of NF-B and related genes in the MM cells..
Study Status Information
Study Activation / Registration Date:
11/03/2004
IRB Review and Approval Date:
07/02/2003
Study Type:
Therapeutic
Recruitment Status:
Open
Projected Accrual:
N/A.
Enrollment Eligibility
If you do not meet the enrollment eligibility, there may be other treatment options for you. Please Contact the Referral Office for more information.
Inclusion Criteria:
1) Multiple myeloma patients who have been previously untreated, are asymptomatic and without serious or imminent complications, have relapsed or failed treatment with conventional treatment or progressed on no or limited maintenance, or are in stable partial remission.2) Bone marrow plasma cells >/= 10% and serum M-protein level >/= 0.5 g/dL and/or urinary Bence Jones protein >/= 100 mg/24 hr. When the bone marrow (BM) plasma cell differential is <10%> 1000/mm^3, platelet count > 100,000/mm^3, Hgb > 10 gms/dL), renal (serum creatinene <>/= 6 months.7) Effective means of contraception for women of child bearing potential.8) Women of child-bearing potential must have a negative pregnancy test.9) Ability to comply with study visit schedule and protocol requirements.
Exclusion Criteria:
1) Pregnant or lactating women.2) Previously untreated patients with high tumor mass, symptomatic or impending fractures, hypercalcemia or plasma cell leukemia.3) Patients with benign monoclonal gammopathy (MGUS) or non-secretory multiple myeloma.4) Significant cardiac disease, dysarrhythmia, or recent H/O MI or ischemia.5) Comorbid condition which renders patients at high risk of treatment complications.6) History of significant neurological or psychiatric disorders including dementia or seizures that would impede consent, treatment or follow-up.7) H/O curcumin or Bioperine supplement in prior 4 weeks.8) Patients on anti-convulsants, anti-coagulant treatment, or anti-arrhythmic medications for cardiac arrhythmia other than atrial fibrillation.